
ABOUT ERGOMED CLINICAL RESEARCH
Established in 1997, Ergomed is a global leader in delivering specialized services in oncology, rare disease, and complex trials to the pharmaceutical and biotech sectors. Our comprehensive support covers the entire clinical trial process, from early phase to post-approval, offering full-service, industry-leading clinical trial management solutions as a trusted partner. Our integrated service model helps life sciences companies meet regulatory obligations, maximize drug development success, and enhance the patient experience.
FEATURED ARTICLES
-
Drawing from extensive experience in early-phase oncology, this guide offers a strategic framework for executing first-in-human (FIH) oncology trials with a patient-centric and risk-based approach.
-
Collaboration between drug development companies and Patient Advocacy Organizations is essential to bridging gaps between stakeholders and advancing rare disease research.
-
In a clinical trial landscape defined by innovation and empathy, oncology CROs are essential to shaping the future of cancer research.
-
First-in-human oncology trials are critical touchpoints in the development of novel cancer therapies, requiring precise scientific execution and a deeply patient-centric approach.
-
As cancer therapies grow more complex and personalized, patient-reported outcomes (PROs) have emerged as a vital component of oncology research and care.
-
Discover how partnering with specialized rare disease CROs allows drug sponsors to accelerate treatment development, navigate trial complexities, and ultimately improve patient outcomes.
-
Examine the transformative landscape of medical monitoring in clinical trials with an emphasis on the shift from conventional retrospective reviews to a proactive, risk-based methodology.
-
Successful execution of rare cancer clinical trials requires strategic patient recruitment, innovative trial design, and specialized expertise from Oncology CROs.
-
By embracing innovative trial models and strategic collaborations, oncology CROs play a pivotal role in bringing novel cancer therapies to market efficiently and effectively.
-
Patient advocacy organizations (PAOs) play a pivotal role in rare disease research by bridging the gap between patient communities and biotech companies.
-
Conducting clinical trials for rare cancers presents unique challenges, making a partnership with an experienced Oncology CRO crucial for overcoming hurdles and ensuring trial success.
CONTACT INFORMATION
Ergomed Clinical Research
Unit 1 Occam Rd.
Guildford, GU2 7HJ
UNITED KINGDOM
Phone: +48 691903990
Contact: Sylwia Domagalska